Mustang Bio (MBIO) Competitors $1.36 0.00 (0.00%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.42 +0.06 (+4.78%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBIO vs. NLSP, BTAI, CANF, TCRT, DRMA, ADIL, SNGX, ONCO, KLTO, and AEZSShould you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include NLS Pharmaceutics (NLSP), BioXcel Therapeutics (BTAI), Can-Fite BioPharma (CANF), Alaunos Therapeutics (TCRT), Dermata Therapeutics (DRMA), Adial Pharmaceuticals (ADIL), Soligenix (SNGX), Onconetix (ONCO), Klotho Neurosciences (KLTO), and Aeterna Zentaris (AEZS). These companies are all part of the "pharmaceutical products" industry. Mustang Bio vs. NLS Pharmaceutics BioXcel Therapeutics Can-Fite BioPharma Alaunos Therapeutics Dermata Therapeutics Adial Pharmaceuticals Soligenix Onconetix Klotho Neurosciences Aeterna Zentaris Mustang Bio (NASDAQ:MBIO) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk. Does the media prefer MBIO or NLSP? In the previous week, NLS Pharmaceutics had 1 more articles in the media than Mustang Bio. MarketBeat recorded 3 mentions for NLS Pharmaceutics and 2 mentions for Mustang Bio. NLS Pharmaceutics' average media sentiment score of 0.96 beat Mustang Bio's score of 0.44 indicating that NLS Pharmaceutics is being referred to more favorably in the news media. Company Overall Sentiment Mustang Bio Neutral NLS Pharmaceutics Positive Do institutionals & insiders believe in MBIO or NLSP? 9.9% of Mustang Bio shares are held by institutional investors. 0.2% of Mustang Bio shares are held by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer MBIO or NLSP? Mustang Bio received 161 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. Likewise, 64.26% of users gave Mustang Bio an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote. CompanyUnderperformOutperformMustang BioOutperform Votes16964.26% Underperform Votes9435.74% NLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% Which has preferable earnings & valuation, MBIO or NLSP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMustang BioN/AN/A-$51.60M-$78.00-0.02NLS PharmaceuticsN/AN/A-$12.17MN/AN/A Do analysts prefer MBIO or NLSP? Mustang Bio presently has a consensus target price of $100.00, suggesting a potential upside of 7,252.94%. Given Mustang Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Mustang Bio is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, MBIO or NLSP? Mustang Bio has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500. Is MBIO or NLSP more profitable? Company Net Margins Return on Equity Return on Assets Mustang BioN/A N/A -172.89% NLS Pharmaceutics N/A N/A N/A SummaryMustang Bio beats NLS Pharmaceutics on 7 of the 12 factors compared between the two stocks. Remove Ads Get Mustang Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBIO vs. The Competition Export to ExcelMetricMustang BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.50M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.026.7921.7217.82Price / SalesN/A225.96376.8894.61Price / CashN/A65.6738.1534.64Price / Book2.035.866.474.00Net Income-$51.60M$141.86M$3.20B$247.23M7 Day PerformanceN/A4.50%2.86%1.45%1 Month Performance-3.55%-12.65%-8.55%-6.24%1 Year Performance-92.57%-11.06%10.58%0.60% Mustang Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBIOMustang Bio2.0091 of 5 stars$1.36flat$100.00+7,252.9%-92.7%$4.50MN/A-0.02100Short Interest ↑NLSPNLS PharmaceuticsN/A$1.42-4.2%N/A+960.1%$5.11MN/A0.006Short Interest ↓News CoverageGap DownBTAIBioXcel Therapeutics4.0014 of 5 stars$1.56-4.3%$42.60+2,630.8%-95.9%$5.00M$2.27M-0.0590Gap DownCANFCan-Fite BioPharma2.2839 of 5 stars$1.41-4.1%$14.00+892.9%-40.0%$4.99M$667,000.00-0.798Analyst ForecastGap DownTCRTAlaunos Therapeutics1.1057 of 5 stars$3.00+1.7%N/A-79.3%$4.80M$10,000.000.0040High Trading VolumeDRMADermata Therapeutics1.8739 of 5 stars$0.88-7.9%$6.00+578.7%-82.7%$4.80MN/A-0.058Short Interest ↑News CoverageGap DownADILAdial Pharmaceuticals3.0175 of 5 stars$0.72+13.7%$8.00+1,011.1%-72.7%$4.73MN/A-0.2220SNGXSoligenix1.5039 of 5 stars$1.87+1.6%N/A-73.4%$4.69M$840,000.00-0.2520Short Interest ↓ONCOOnconetix0.9042 of 5 stars$0.07flatN/A-98.9%$4.65M$1.87M0.0012Short Interest ↓Gap DownKLTOKlotho NeurosciencesN/A$0.16+6.2%N/AN/A$4.62MN/A0.00N/AGap DownAEZSAeterna ZentarisN/A$2.56-5.7%N/A-62.7%$4.59M$2.37M-0.1720Gap Down Remove Ads Related Companies and Tools Related Companies NLSP Alternatives BTAI Alternatives CANF Alternatives TCRT Alternatives DRMA Alternatives ADIL Alternatives SNGX Alternatives ONCO Alternatives KLTO Alternatives AEZS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBIO) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MBIO Stock Free MBIO Stock Alerts